Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3).

Date publication

juillet 2024

Journal

Clinical and translational radiation oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr LEPAGE Côme

Tous les auteurs :
de Rauglaudre B, Piessen G, Jary M, Le Malicot K, Adenis A, Mazard T, D'Journo XB, Petorin C, Buffet-Miny J, Aparicio T, Guimbaud R, Vendrely V, Lepage C, Dahan L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38974185

Résumé

Radiotherapy combined with fluorouracil (5FU) and cisplatin for locally advanced esophageal cancer is associated with a 20-25% pathologic complete response (pCR) rate. Cetuximab increases the efficacy of radiotherapy in patients with head and neck carcinomas. The aim of this phase I/II trial was to determine the optimal doses and the pCR rate with chemoradiotherapy (C-RT) plus cetuximab.

Mots clés

Cetuximab, Cisplatin, Esophageal carcinoma, Fluorouracil, Locally advanced, Neoadjuvant, Phase I/II trial, Radiochemotherapy

Référence

Clin Transl Radiat Oncol. 2024 07;47:100804